Treatment of behçet's disease with granulocyte and monocyte adsorption apheresis

Kanekura, Takuro; Gushi, Akira; Iwata, Masahiro; Fukumaru, Seita; Sakamoto, Ryoko; Kikuchi, Kôichi; Maruyama, Ikuro; Kanzaki, Tamotsu

doi:10.1016/j.jaad.2003.12.023

Cited by 33 publications

(31 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We first reported the beneficial effects of GMA in a patient with pyoderma gangrenosum, a condition that is often associated with ulcerative colitis, and proposed that it might be useful for treating skin disorders with prominent granulocytic infiltration . We continued our study of the clinical effectiveness of GMA therapy and presented evidence of its efficacy in patients with recalcitrant skin disorders attributable to activated granulocytes including BD . .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Granulocyte and monocyte adsorption apheresis for Behçet's disease in a pregnant woman

Higashi

Shimokawa

Kawai

et al. 2013

The Journal of Dermatology

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Based on this and previous experience and in vitro observations, we posit that GMA is a useful treatment modality for refractory skin diseases attributable to activated granulocytes. Our favorable experience in the present case suggests that GMA is safe and useful in pregnant and non‐pregnant patients.…”

Section: Discussionmentioning

confidence: 99%

Granulocyte and monocyte adsorption apheresis for Behçet's disease in a pregnant woman

Higashi

Shimokawa

Kawai

et al. 2013

The Journal of Dermatology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Mutations in MEFV , an autoinflammatory gene, have been identified in some cases of Sweet's syndrome [16]. GMA therapy has shown efficacy in several autoinflammatory and neutrophilic diseases such as PASH syndrome [17], DITRA (pustular psoriasis) [18], palmoplantar pustulosis [19], and Behçet's disease [20]. Although the efficacy of GMA therapy in Sweet's syndrome has been reported in 1 patient [14], it has not been fully described.…”

Section: Discussionmentioning

confidence: 99%

Sweet’s Syndrome Successfully Treated with Granulocyte and Monocyte Adsorption Apheresis

et al. 2017

View full text Add to dashboard Cite

Sweet’s syndrome is a neutrophilic dermatosis characterized by an abrupt onset of painful erythematous lesions showing neutrophilic infiltrates in the dermis. Fever and an elevated neutrophil level are generally observed. Sweet’s syndrome may be idiopathic, malignancy-associated, or drug-induced (mainly involving granulocyte colony-stimulating factor (G-CSF) administration). Although systemic corticosteroids are usually effective, the symptoms of Sweet’s syndrome recur in some refractory cases. Herein, we report a case of a 55-year-old Japanese woman with recurrent symptoms of fever (>39°C) and painful erythematous lesions on her four extremities, trunk, and neck. Laboratory findings revealed leukocytosis and high levels of C-reactive protein (CRP) and G-CSF. She was diagnosed with a recurrence of Sweet’s syndrome, and was exclusively treated with granulocyte and monocyte adsorption apheresis (GMA) therapy once a week for 3 consecutive weeks. After the first session of GMA therapy, all symptoms including the erythematous lesions and fever were completely resolved, and serum G-CSF level was reduced. Leukocyte count, neutrophil count, serum amyloid A protein, and CRP levels were restored within normal ranges by 2 weeks. Thus, GMA therapy can successfully treat a patient with recurrent Sweet’s syndrome, potentially related to the restoration of elevated serum G-CSF levels.

show abstract

“…The efficacy of GCAP has been reported in various skin diseases and related disorders attributable to activated neutrophils, such as pyoderma gangrenosum, 9–11 psoriatic arthritis, 12 SLE skin rash, 13 adult Still’s disease, 14 Behçet’s disease, 15 leg ulcer with rheumatoid arthritis, 16 cutaneous allergic vasculitis 17 and pustular psoriasis 7,8 . These reports suggested that GCAP could be effective in treating not only the skin lesions but also arthropathies 6,12,18 …”

Section: Discussionmentioning

confidence: 99%

Granulocyte and monocyte adsorption apheresis for generalized pustular psoriasis

Shukuya

Hasegawa

Niwa

et al. 2011

The Journal of Dermatology

View full text Add to dashboard Cite

Granulocyte and monocyte adsorption apheresis (GCAP) is an extracorporeal circulation therapy that removes activated granulocytes and monocytes. GCAP was initially approved for the treatment of ulcerative colitis, which is attributed to activated granulocytes and macrophages that infiltrate the target tissues. Generalized pustular psoriasis (GPP) is also supposed to be caused by activated neutrophils. In this study, we treated two patients with refractory GPP by using GCAP. Patient 1, a 68-year-old woman who had liver cirrhosis, underwent seven GCAP sessions. Patient 2, a 26-year-old woman who had systemic lupus erythematosus and had been treated with systemic corticosteroids, underwent eight GCAP sessions. In both patients, GCAP resulted in an immediate improvement in skin lesions and fever reduction, without any adverse effects. We suggest that GCAP is an effective therapy for refractory GPP.

show abstract

Treatment of behçet's disease with granulocyte and monocyte adsorption apheresis

Cited by 33 publications

References 9 publications

Granulocyte and monocyte adsorption apheresis for Behçet's disease in a pregnant woman

Granulocyte and monocyte adsorption apheresis for Behçet's disease in a pregnant woman

Sweet’s Syndrome Successfully Treated with Granulocyte and Monocyte Adsorption Apheresis

Granulocyte and monocyte adsorption apheresis for generalized pustular psoriasis

Contact Info

Product

Resources

About